Allergan and Syntaxin to Co-Develop Bacterial-Based Therapeutic Proteins

Syntaxin Ltd. (Wiltshire, UK, www.syntaxin.com), a 2005 spinout from the UK Health Protection Agency, has entered into a research and license arrangement with Allergan (Irvine, CA, www.allergan.com). Under the agreement, the companies will jointly fund research to use Syntaxin’s technology to engineer clostridial endopeptidase-based proteins for cell targeting. This agreement follows an earlier collaboration between the two companies in the field of pain.